Synergistic Cranial Nerve Stimulation Systems

Integrating innovative technologies like AI, IoT, blockchain, and novel biomaterials with implantable neuromodulation devices to create more effective and personalized treatments for various disorders, including sleep apnea, chronic pain, and movement disorders.

The original patent disclosed methods for stimulation of cranial nerves to treat various disorders. However, these methods had limitations in terms of signal efficacy, patient confidentiality, and real-time monitoring. The new inventive concept addresses these limitations by combining the original patented technology with distinct technologies to create a more powerful system.

The inventive concept comprises an implantable neuromodulation device integrated with a machine learning module to predict sleep disorder episodes and adjust the neuromodulation signal accordingly. Additionally, a blockchain-based secure communication protocol ensures data integrity and patient confidentiality. An IoT-based sensor network monitors patient physiological data and adjusts the neuromodulation signal in real-time. Novel biomaterial-based electrode designs enhance signal efficacy. AI-powered algorithms analyze patient-specific data to optimize the neuromodulation signal for individualized treatment outcomes.

The new claims introduce the integration of AI, IoT, blockchain, and novel biomaterials with implantable neuromodulation devices, which is not disclosed in the original patent. This synergistic combination provides a more effective and personalized treatment approach, which is not obvious from the original patent.

Alternative embodiments could include using different machine learning algorithms, varying the type of IoT sensors, or incorporating additional distinct technologies. Variations could include adapting the system for different disorders or using different biomaterials for the electrode design.

The inventive concept has significant commercial potential in the medical device industry, particularly in the fields of sleep disorders, chronic pain, and movement disorders. The target market includes hospitals, clinics, and medical research institutions.